Studies have shown that active fund managers routinely underperform the S&P500 index*​

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)

ACAD Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
132.60%
Analyst Rating:
BUY
Analyst Forecast (1yr):
53.70%

ACAD Stock Analysis

ACAD PE Ratio: 9.7

ACAD PEG Ratio: 0.1

ACAD Forward EPS Growth (12 month): 115.40%

ACAD PS Ratio: 3.4

ACAD PSG Ratio: 0.3

ACAD Forward Revenue Growth (12 month): 11.80%

ACAD Articles

No data was found